tucatinib

EGFR-sparing HER2 kinase inhibitor

approved in met. HER2+ BC incl. w/ brain met.

from optimization of known TKIs

Mol. Cancer Ther., Apr. 1, 2020

Array / Cascadian Tx / Seattle Genetics

Tucatinib is the third approved HER2 kinase inhibitor (after lapatinib and neratinib), but differentiates itself due to its selectivity against the closely related EGFR, which is hypothesized to be a…


 become a member to continue reading

Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.

  • Stay up-to-date and save more time with exclusive members-only content
  • On-board new team members with educational content and case studies
  • Generate ideas and discussion with easy-to-read slide decks
  • Generate ideas and discussion with easy-to-read slide decks